Publications by authors named "Yury G Shvarts"
Article Synopsis
- Patients with severe COVID-19 pneumonia have limited treatment options, and opaganib is an oral medication being researched to help those hospitalized.
- A clinical trial conducted in 57 locations from August 2020 to July 2021 compared opaganib to a placebo over 14 days, focusing on whether patients could stop needing supplemental oxygen by day 14.
- Although the primary results showed no significant general benefit, post-hoc analysis indicated that patients with low oxygen levels at baseline may experience better outcomes with opaganib, including reduced intubation rates and lower mortality, suggesting the need for further studies in this specific group.
Purpose: We evaluated gefapixant, a P2X3 receptor antagonist, in participants with recent-onset (≤ 12 months) refractory chronic cough (RCC) or unexplained chronic cough (UCC).
Methods: Participants (≥ 18 years of age; ≥ 40 mm on a 100-mm cough severity visual analog scale [VAS] at screening and randomization) with chronic cough for < 12 months were enrolled in this phase 3b, double-blind, placebo-controlled, parallel group, multicenter study (NCT04193202). Participants were randomized 1:1 to gefapixant 45 mg BID or placebo for 12 weeks with a 2-week follow-up.
Efficacy and safety of the combined metabolic medication, containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multicenter randomized, double-blind, placebo-controlled parallel group clinical trial (CYLINDER).
BMJ Open Diabetes Res Care
June 2022
Introduction: Antioxidants may have positive impact on diabetic polyneuropathy (DPN), presumably due to alleviation of oxidative stress. We aimed to evaluate the efficacy and safety of combination of antioxidants: succinic acid, inosine, nicotinamide, and riboflavin (SINR) in the treatment of DPN.
Research Design And Methods: In a double-blind, placebo-controlled clinical trial, men and women aged 45-74 years with type 2 diabetes and symptomatic DPN, with initial Total Symptom Score (TSS) ˃5, were randomized into experimental (n=109) or placebo (n=107) group.